Aarti Pharmalabs Ltd (AARTIPHARM) is currently trading at 789.30 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Aarti Pharmalabs is a vertically integrated Indian manufacturer of generic APIs, intermediates, HPAPIs and xanthine derivatives, and a growing small-molecule CDMO/CMO provider with three USFDA-approved units, seven manufacturing sites and a focus on regulated markets across the USA, EU, Japan and ROW. Aarti Pharmalabs is the largest Indian manufacturer of Xanthine derivatives with ~15–20% global share today and is building incremental capacity from 5,000 to 9,000 MTPA at Tarapur to target 20–25% global share, leveraging a China+1 tailwind and multiple beverage and pharma customer contracts. The CDMO/CMO vertical is a strategic growth lever: 21 customers and 59 active projects (40 commercial), CDMO revenue rose from INR 208 crore in FY25 and management targets 30–40% growth for FY26E, while Atali greenfield is designed to materially increase intermediates and CDMO throughput. Financials show resilience but near-term stress: 9M-FY26 standalone revenue INR 12,179 million (down 1.9% Y/Y), EBITDA margin ~22%, PAT down materially due to higher depreciation and finance costs from capex; net debt/equity rose to ~0.26x in H1-FY26 as expansion spending accelerated. The company pairs R&D and sustainability credentials—three R&D centres, 116 process scientists, 62 patents filed and ecovadis GOLD plus CDP engagement and renewable projects (21 MW solar) intended to supply roughly half of power needs and reduce operating costs and carbon footprint.

Over the past 52 weeks, Aarti Pharmalabs Ltd has traded between a low of ₹583.85 and a high of ₹946.45. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Aarti Pharmalabs Ltd has a market capitalization of approximately 7,516.00. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Aarti Pharmalabs Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 35.26 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 7,516.00 Cr, Aarti Pharmalabs Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Aarti Pharmalabs Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Aarti Pharmalabs Ltd is 35.26. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

The dataset lists a ₹2 final dividend for equity shares with an ex-date of 15 Sep 2026 and a record date of 15 Sep 2026.

In Q1 FY27, consolidated operational revenue was ₹535.8 crore and consolidated PAT was ₹76.1 crore. Standalone operational revenue was ₹534.6 crore and standalone PAT was ₹71.3 crore.

The board approved unaudited Q1 FY27 financial results (quarter ended June 30, 2026), a ₹149 crore capex for an intermediate block capacity addition, and leadership changes effective October 1, 2026.